WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317960
CAS#: 54-31-9 (free base)
Description: Furosemide is a loop diuretic that inhibits the Na+/2Cl-/K+ (NKCC) symporter. It also acts as a non-competitive antagonist at GABAA receptors with ~ 100-fold greater selectivity for α6-containing receptors than α1-containing receptors.
Hodoodo Cat#: H317960
Name: Furosemide
CAS#: 54-31-9 (free base)
Chemical Formula: C12H11ClN2O5S
Exact Mass: 330.01
Molecular Weight: 330.740
Elemental Analysis: C, 43.58; H, 3.35; Cl, 10.72; N, 8.47; O, 24.19; S, 9.69
Related CAS #: 42461-27-8 (HCl). 54-31-9 (free) 41733-55-5 (sodium)
Synonym: Furosemide; Frusemide; Lasix; Furanthril; Furosemid; Salix (brand of furosemide); Furosemide Monohydrochloride; Furosemide Monosodium Salt;
IUPAC/Chemical Name: 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
InChi Key: ZZUFCTLCJUWOSV-UHFFFAOYSA-N
InChi Code: InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
SMILES Code: C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
Appearance: White to light yellow crystalline powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 330.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Das PK, Maurya SK, Nath SS, Kumar T, Rao N, Shrivastava N. Furosemide Stress Test and Renal Resistive Index for Prediction of Severity of Acute Kidney Injury in Sepsis. Cureus. 2023 Aug 30;15(8):e44408. doi: 10.7759/cureus.44408. PMID: 37791174; PMCID: PMC10543092.
2: Janssen KM, Cho JY, Stone K, Kirsch AJ, Linam LE. Decreased percent change in renal pelvis diameter on diuretic functional magnetic resonance urography following administration of furosemide may help characterize unilateral uretero- pelvic junction obstruction. J Pediatr Urol. 2023 Aug 22:S1477-5131(23)00329-7. doi: 10.1016/j.jpurol.2023.08.014. Epub ahead of print. PMID: 37704530.
3: Mazzoldi C, Aspidi F, Romito G. Dermatologic adverse effect of subcutaneous furosemide administration in a cat. Open Vet J. 2023 Aug;13(8):1027-1031. doi: 10.5455/OVJ.2023.v13.i8.9. Epub 2023 Aug 31. PMID: 37701668; PMCID: PMC10495090.
4: Wichmann S, Lange T, Perner A, Gluud C, Itenov TS, Berthelsen RE, Nebrich L, Wiis J, Brøchner AC, Nielsen LG, Behzadi MT, Damgaard K, Andreasen AS, Strand K, Järvisalo M, Strøm T, Eschen CT, Vang ML, Hildebrandt T, Andersen FH, Sigurdsson MI, Thomar KM, Thygesen SK, Troelsen TT, Uusalo P, Jalkanen V, Illum D, Sølling C, Keus F, Pfortmueller CA, Wahlin RR, Ostermann M, Aneman A, Bestle MH. Furosemide versus placebo for fluid overload in intensive care patients-The randomised GODIF trial second version: Statistical analysis plan. Acta Anaesthesiol Scand. 2023 Sep 11. doi: 10.1111/aas.14320. Epub ahead of print. PMID: 37691474.
5: Singh S, Goel S, Duhan S, Chaudhary R, Garg A, Tantry US, Gurbel PA. Effect of Furosemide Versus Torsemide on Hospitalizations and Mortality in Patients With Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Am J Cardiol. 2023 Sep 5;206:42-48. doi: 10.1016/j.amjcard.2023.08.079. Epub ahead of print. PMID: 37677884.
6: Guan C, Li C, Xu L, Che L, Wang Y, Yang C, Zhang N, Liu Z, Zhao L, Zhou B, Man X, Luan H, Xu Y. Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool. Eur J Med Res. 2023 Sep 2;28(1):312. doi: 10.1186/s40001-023-01306-0. PMID: 37660080; PMCID: PMC10474726.
7: Koronaiou LA, Nannou C, Evgenidou E, Panagopoulos Abrahamsson D, Lambropoulou DA. Photo-assisted transformation of furosemide: Exploring transformation pathways, structure database and suspect and non-target workflows for comprehensive screening of unknown transformation products in wastewaters and landfill leachates. Sci Total Environ. 2023 Aug 26;904:166599. doi: 10.1016/j.scitotenv.2023.166599. Epub ahead of print. PMID: 37640083.
8: Benzi JRL, Rocha A, Colombari JC, Pego AMG, Dos Santos Melli PP, Duarte G, Lanchote VL. Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women. J Pharm Biomed Anal. 2023 Oct 25;235:115635. doi: 10.1016/j.jpba.2023.115635. Epub 2023 Aug 11. PMID: 37634358.
9: Ahmad Cheema H, Azeem S, Ejaz A, Khan F, Muhammad A, Shahid A, Nashwan AJ, Maqsood MH, Dani SS, Mentz RJ, Fudim M, Fonarow GC. Efficacy and safety of torsemide versus furosemide in heart failure patients: A systematic review of randomized controlled trials. Clin Cardiol. 2023 Aug 22. doi: 10.1002/clc.24088. Epub ahead of print. PMID: 37608566.
10: Iwamoto Y, Kimura T, Ohnishi M, Kusano T, Takenouchi H, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, Tatsumi F, Shimoda M, Nakanishi S, Kaku K, Mune T, Kaneto H. Simple standing test without furosemide is useful in the diagnosis of primary aldosteronism. Sci Rep. 2023 Aug 17;13(1):13381. doi: 10.1038/s41598-023-40574-y. PMID: 37591913; PMCID: PMC10435472.
11: Raina R, Sethi SK, Agrawal G, Wazir S, Bajaj N, Gupta NP, Tibrewal A, Vadhera A, Mirgunde S, Balachandran B, Sahoo J, Afzal K, Shrivastava A, Bagla J, Krishnegowda S, Konapur A, Soni K, Alhasan K, McCulloch M, Bunchman T. Use of furosemide in preterm neonates with acute kidney injury is associated with increased mortality: results from the TINKER registry. Pediatr Nephrol. 2023 Aug 15. doi: 10.1007/s00467-023-06086-7. Epub ahead of print. PMID: 37581700.
12: Hughes A. Letter to the Editor: Using Randomized Controlled Trials to Evaluate the Effectiveness of Subcutaneous Furosemide in Advanced Heart Failure Patients With Palliative Care Needs. J Palliat Med. 2023 Aug;26(8):1035-1036. doi: 10.1089/jpm.2023.0310. PMID: 37579228.
13: Kamio T, Ikegami M, Machida Y, Uemura T, Chino N, Iwagami M. Machine learning-based prognostic modeling of patients with acute heart failure receiving furosemide in intensive care units. Digit Health. 2023 Aug 11;9:20552076231194933. doi: 10.1177/20552076231194933. PMID: 37576718; PMCID: PMC10422900.
14: Li ZK, Zheng P. Acute pancreatitis caused by tigecycline and furosemide combination treatment and hypofibrinogenemia caused by tigecycline: A case report. Int J Clin Pharmacol Ther. 2023 Oct;61(10):466-470. doi: 10.5414/CP204337. PMID: 37548456.
15: Yilmaz B. Release of nifedipine, furosemide, and niclosamide drugs from the biocompatible poly(HEMA) hydrogel structures. Turk J Chem. 2022 Sep 1;46(5):1710-1722. doi: 10.55730/1300-0527.3474. PMID: 37529747; PMCID: PMC10390117.
16: Li C, Ren Q, Li X, Han H, Xie K, Wang G. Association between furosemide administration and clinical outcomes in patients with sepsis-associated acute kidney injury receiving renal replacement therapy: a retrospective observational cohort study based on MIMIC-IV database. BMJ Open. 2023 Jul 30;13(7):e074046. doi: 10.1136/bmjopen-2023-074046. PMID: 37518073; PMCID: PMC10387626.
17: Su Y, Zhang YJ, Tu GW, Hou JY, Ma GG, Hao GW, Xu RH, Luo Z. Furosemide Responsiveness Predicts Acute Kidney Injury Progression After Cardiac Surgery. Ann Thorac Surg. 2023 Jul 23:S0003-4975(23)00728-2. doi: 10.1016/j.athoracsur.2023.07.011. Epub ahead of print. PMID: 37488003.
18: To A, Davila C, Stroope S, Walton R. Case report: Resolution of oligo-anuric acute kidney injury with furosemide administration in a cat following lily toxicity. Front Vet Sci. 2023 Jul 5;10:1195743. doi: 10.3389/fvets.2023.1195743. PMID: 37476822; PMCID: PMC10354244.
19: Siddiqi AK, Javaid H, Ahmed M, Dhawadi S, Batool L, Zahid M, Muslim MO, Naeem K, Mahmood F, Hussain A. Clinical Outcomes With Furosemide Versus Torsemide in Patients With Heart Failure: An Updated Systematic Review and Meta- Analysis. Curr Probl Cardiol. 2023 Jul 13;48(11):101927. doi: 10.1016/j.cpcardiol.2023.101927. Epub ahead of print. PMID: 37453532.
20: Kulkarni NS. No Benefit With Torsemide Over Furosemide for Posthospitalization Treatment of Heart Failure. Am Fam Physician. 2023 Jul;108(1):Online. PMID: 37440752.
